Familial dysbetalipoproteinemia
Alternative names:
type III hyperlipoproteinemia
Treatment:
The goal of treatment is to control underlying conditions such as obesity, hypothyroidism, and diabetes when possible.
The restriction of excess calories and the reduction of saturated fats and cholesterol should significantly reduce cholesterol levels.
If high cholesterol and triglyceride levels persist with maximum dietary treatment, cholesterol lowering agents should be started. Nicotinic acid (niacin), clofibrate, or gemfibrozil are drugs that have effectively reduced cholesterol and triglycerides in people affected with dysbetalipoproteinemia.
Expectations (prognosis):
Individuals with this form of hyperlipidemia have a significantly increased risk for coronary artery disease. With treatment, most people show a significant reduction in lipid levels.
Complications:
Calling your health care provider:
Call your health care provider if symptoms worsen, do not improve with treatment, or new symptoms develop.
|
